It is a big challenge to identify patient-specific drug combinations based on cancer omics data. However, most conventional methods used for identifying personalized therapies require large sample sizes and focuse on the population as a whole and we still lack a feasible mathematical framework to circumvent this key problem in the clinical application of precision medicine. This work presents a personalized drug controller method (PDC) to identify drug combinations of individual cancer patients, by exploring the transition state information from a disease state to a normal state, thus providing novel insights into tumor heterogeneity in complex patient ecosystems.
Introduction
The clinical efficacy of targeted cancer therapies is hampered by the development of acquired resistance. In an effort to combat targeted therapy drug resistance, drug combinations are increasingly being used as standard of care treatment strategies for several cancers (Jia et al. 2009) . A current critical challenge is how to develop efficient in silico methods for discovering effective drug combinations from the analysis of large data sets and complex dynamic processes. The number of potential drug combinations generated from such analyses is astronomical, and these combinations cannot all be tested in a rational and rigourous manner. Therefore, scientists are inundated with large amounts of data, and no feasible way of distilling said data into viable drug combinations (Sun et al. 2013) . Recent studies have highlighted the importance of targeting key oncogenes for disease control. Designing novel combinatorial strategies to target these fundamental cancer genes may result in synergistic antitumor activity and broader application of current therapies (Phillips 2008; Han et al. 2017; Quan et al. 2018; Yip et al. 2018) . A number of systems biology tools have been developed to identify key genes, which can be specifically targeted for drug development (Bush et al. 2006; Hunter et al. 2007; Liu et al. 2010; Wan et al. 2010; Ling et al. 2011; Zhang 2012; Chang et al. 2015; Wright and Ziegler 2017) .
Cancer is increasingly viewed as a "patient ecosystem", a system in which tumor genes cooperate and can also adapt and evolve to changing conditions in their microenvironment (Merlo et al. 2006; Greaves and Maley 2012; van der Wijst et al. 2018 ). Precision or personalized medicine requires a different type of clinical trial that focuses on individual, not average, responses to therapy. It has been reported that at present, some of the most commonly prescribed drugs are effective in less than 25% of the people for whom they are prescribed (Schork 2015) . Therefore, recognition that researchers need to consider individual heterogeneity is driving huge interest for identifying drugs in precision medicine. However, most of the existing detection methods for combinatorial drugs ignore personalized sample information, and fail to identify patient-specific combinational drugs, which is a necessary and important facet of precision medicine. Therefore, new techniques are urgently needed to better understand tumor heterogeneity and its impact on cancer development, and to generate personalized drug combinations.
To solve this problem, we introduced network control theory to model the control role of drugs (as controllers) on the transition state of gene co-expression networks from tumor state to normal state. Network control theory considers how to choose key network elements as drivers, the activation of which may drive the entire network towards a desired control objective or state based on proper control signals Gao et al. 2014; Ruths and Ruths 2014; Wu et al. 2014a; Guo et al. 2017; Guo et al. 2018d) . Recent studies on network controllability have offered powerful mathematical frameworks to understand diverse biological systems at a network level (Jgt et al. 2017; Guo et al. 2018c; Li et al. 2018 ). However, these existing methods mainly focus on the statistical study of tumor heterogeneity at a population level, and cannot be directly applied to the analysis of individual patients. This is primarily due to a gap between the network control theory and the applications in the personalized patient system. More efficient methods are needed to obtain personalized state transition networks that capture the phenotypic transitions between normal and disease states, which is a rate-limiting step of network control methods.
However, most of the current network control methods assume unspecified linear dynamics or linearized non-linear dynamics in the complex networks, which may only give an incomplete view of the network control properties of the nonlinear dynamic biological system. To address these limitations, we present a novel personalized drug controller method (PDC), which sheds light on the cancer transition network from a cancer state to a normal state, as well as on the cancer ecosystem of each patient at an individual level by integrating patient data with the network control framework. The impetus behind PDC was to develop efficient models for pushing a complex, nonlinear, individual biological system from disease attractor (i.e., a steady disease state) to normal attractor (i.e., a steady normal state) through potential drug action on specific target genes. Our PDC framework mainly includes two parts: a paired Single-Sample-Network (SSN) method for constructing the state transition network between normal state and tumor state; and a novel nonlinear control scheme based on undirected networks (NCUA) for detecting both personalized key control genes (KCGs) and personalized combinatorial drugs specific for KCGs.
We have applied PDC to breast cancer (BRCA) and lung cancer (LUSC) datasets obtained from TCGA for the benchmark analysis. We discovered that: i) the nonlinear control method NCUA performed better than other existing network control methods in terms of precision for discovering personalized combinatorial drugs; and ii) the prior gene (or protein) interaction network can improve the precision for predicting combinational drugs. Actually, one significant advantage of our method is to explore network and structural statistics of patient-specific genes, including tests of mutations, differential expression, hub characteristic, and of co-occurrence in gene interaction networks. The following unexpected findings were generated from these analyses: i) the personalized KCGs tended to be genes with insignificant differential expression;
ii) the mutational profiles were specific to each patient; and iii) the KCGs were structurally enriched in hub genes and functionally connected in gene interaction networks for most cancer patients.
To elucidate the mechanisms of drug-target action, we quantified the side effects of drug pairs on KCGs by evaluating the side effect score for each patient (Torres and Altafini 2016) . We estimated the side effect of all of the drug pairs on KCGs for each patient and obtained the number of drug pairs with an aggravating effect (side effect score >0), and the number of drug pairs with an enhancing effect (side effect score <0). By considering the drug pairs with an aggravating effect or an enhancing effect, we found that the patient samples in the breast cancer TCGA dataset could be clearly classified into different groups with significant risk assessment. This demonstrates that combinational drug side effect signatures may enable patient stratification and prognostication based on the actionability of drug combinations. In conclusion, our PDC can provide key insights into tumor heterogeneity and its impact on the development and clinical application of personalized cancer therapy.
Results

Overview of personalized drug controller
To identify personalized combinational drugs, we designed PDC to model the role of drugs (as controllers) on the transition from tumor state to normal state. The steps of PDC mainly included: 1) a paired Single-Sample-Network (SSN) method was developed to construct the transition state gene network between a normal state and a tumor state. In that, the co-expression network for each normal and tumor sample was constructed by SSN (Liu et al. 2016 ) and we integrated the two co-expression networks and the gene interaction networks to obtain the personalized transition state gene network between normal state and tumor state; and 2) a novel nonlinear structural control method (NCUA) based on feedback vertex sets (Fiedler et al. 2013a; Mochizuki et al. 2013 ) was developed and used for identifying personalized key control genes (KCGs). This was done to ensure that the system state would asymptotically be changed in the personalized transition network, and further prioritize the personalized combinatorial drugs by considering the control impact on the personalized KCGs. These two main methodologies are described in more detail in the methods section. Our PDC consisted of two main parts. One is a paired single sample network method (paired SSN) rather than an original SSN, which we used to construct personalized transition state gene networks. In these networks, edges existed in both the gene interaction network and the differential co-expression network for each patient (Figure 1 and Figure S1 (a)) based on integration of the matched genetic information of normal and disease samples from the same patient. The personalized transition state gene networks are undirected and weighted graphs in which nodes represent genes, and a pair of nodes denotes the significant co-expression difference between normal state and tumor state in the gene interaction networks, and the edge weight indicates the differential fold change co-expression between normal sample and tumor sample for a specific patient. For the second part of PDC, we designed an improved nonlinear network control method based on feedback vertex sets (NCUA), where we considered the optimization of target nodes towards the desired control objective, instead of only evaluating the controllability of the networks. To demonstrate the effectiveness of NCUA as an important factor, we also evaluated the precision of other existing control methods to predict drug combinations, including Liu's linear network control method (Liu method) ), Minimum Dominating Sets based control method (MDS method) (Nacher and Akutsu 2012), Single sample controller method (SCS method) (Guo et al. 2018a) , and minimum Directed-networks Feedback vertex set based method (DFVS method) (Chakradhar et al. 1995; Fiedler et al. 2013b ). The detailed computational procedures are listed in the Supplementary Methods section of the Supplementary Manuscript). The impetus behind PDC was to design and integrate methods for constructing personalized transition state gene networks to capture the phenotypic transitions between normal and disease attractors, and developing control principles where we push a complex, nonlinear individual system in cancer from disease attractor to normal attractor through drug activation to a feasible subset of network nodes. The assumption of our PDC is that a gene network exists in each attractor (normal attractor or disease attractor) for each patient, where each edge denotes the co-expression of a pair of interacted genes. (b) We developed a paired single sample network method (paired SSN) for constructing personalized transition state gene networks to capture the phenotypic transitions between normal and disease state through the integration of expression data and gene interaction networks. By considering the nonlinear dynamics of transition state gene networks, we also designed a novel nonlinear network control method based on feedback vertex set control (NCUA), where we considered the optimization of input nodes (personalized KCGs) towards the desired control objective, instead of only evaluating the controllability of the networks. Based on their impact on the personalized KCGs (red circles), we extracted the subnetworks connecting the drugs and personalized KCGs (red edges) and prioritized the personalized drug combinations. The details of PDC are depicted in Supplementary Figure S1 .
Collection of benchmark datasets and reference networks
The personalized drug controller strategy (PDC) frames the identification of personalized drug combinations as a network control problem in a two-layer multimodal network of two node types: the personalized transition state gene network, and the drug and genes interaction network. On one hand, the personalized transition state gene network describes gene relationships to capture the phenotypic transitions between normal and disease states. On the other hand, the drug and genes links describe the genes targeted by a given drug. Second, to obtain the drug-gene interaction data, we searched DCDB ) and the Drug-Gene Interaction database (DGIdb), DrugBank and the Therapeutic Target Database (TTD) (Law et al. 2014; Hong et al. 2016; Wagner et al. 2016) , and 342 documented combinations containing the predicted combinatorial drugs that can target the synthetic lethal gene pairs, were identified (Quan et al. 2018 ).
Among them, 32 and 17 were reported in the literature for efficiently treating breast cancer and lung cancer, respectively. In this work, to analyze the risk assessment of cancer patients, the human drug-target network with positive and negative interactions information was used to add another functional element to the network-based investigation of drug-target interactions, including the activation, inhibition, and pharmacological actions of drug-gene interactions (Torres and Altafini 2016) .
Analysis of the functional enrichment of KCGs with the Unified Medical Language
System (UMLS) and UMLS::similarity identified 2341 breast cancer-related genes (Aronson 2001; Liu et al. 2014a; Quan et al. 2018 ). All of the data resources used in this study, including the cancer benchmark datasets and the reference network datasets, and the source code of PDC with NCUA and other network control methods, are provided for free at http://sysbio.sibcb.ac.cn/cb/chenlab/software.htm.
PDC accurately prioritizes personalized anti-cancer drug combinations
By calculating the number of targeted KCG for each of the drug combinations, PDC allowed us to rank the anti-cancer drug combinations and select the top k (k=1,2,…5) ranked anti-cancer drug combinations for each patient. To verify the effectiveness of our PDC approach, the drug combinations annotated in the Clinical Anti-cancer Combinational drugs (CAC) were applied to assess the precision of the top-ranked anti-cancer drug combinations from PDC using the formula:
where k p denotes the fraction of the top k predicted drug combinations within CAC for treating cancer.
The key aspect of our PDC model is using NCUA (a nonlinear structure control method) to identify the KCGs (The details are seen in Methods). By comparing the performance of NCUA to that of other network control methods, i.e., Liu method , MDS method(Nacher and Akutsu 2012), SCS method (Guo et al. 2018a) , and DFVS method (Chakradhar et al. 1995; Fiedler et al. 2013b) , the highest precision can be achieved in NCUA's predictions as seen in 
Assessing patient risk by side effect quantification on KCGs
Another important task in the context of multi-component therapies is to understand the joint effect of two or more drugs acting on the targets (Campillos et al. 2008) . By targeting the KCGs (results on SynLethDB network) within the cancer census gene sets (Hou and Ma 2014; Jia and Zhao 2014; Bertrand et al. 2015) , we calculated the number of drug pairs with aggravating effects (side effect score >0) and the number of drug pairs with enhancing effects (side effect score <0). Based on this data, we found that patients in the breast cancer dataset could be classified into three distinct subtypes, as shown in Figure 5 (a). In Figure S5 , we also show the results of the comparative analysis of other schemes, including PDC results within cancer census gene sets on MGIN and sPPI network and PDC results alone. The results demonstrate that the SynLethDB network provided better patient classification.
We also considered the fraction of patient deaths as an index of significant risk assessment, as listed in we give the results of patient stratification and prognostication based on our identified subtypes, which support that the side effect signature of drug combinations may enable patient stratification and prognostication with significant risk assessment. To obtain a sufficiently comprehensive list of breast cancer-related genes, 2341 breast cancer-related genes were identified by using the Unified Medical Language System (UMLS) (Aronson 2001; Liu et al. 2014a; Quan et al. 2018 demonstrating that the identified enrichment pathways were active in cancer development; ii) the related pathway KCGs were also structurally enriched in hub genes; and iii) the side effect level value of high risk pathways were higher, demonstrating the validity of our predicted high risk pathways. 
Discussion
As drug combinations become a mainstay in cancer therapy, integrative analytical approaches are being increasingly incorporated into cancer genomics. It is already recognized that cancer patients are not all the same and unique drug combinations may be relevant for individual patients or a specific subset of patients (Schork 2015) .
Tumor heterogeneity in cancer patients has been a major obstacle in understanding cancer and in applying precision medicine to the treatment of cancer. Many conventional methods used to study cancer heterogeneity require large sample sizes and focus on statistical analysis at the population level. Therefore, it remains challenging to predict personalized drug combinations based on patient-specific data rather than on patient cohort data. As a result, new analytical tools are needed to address this problem.
An increasing number of studies have demonstrated that targeting key disease genes can provide critical information for drug discovery and drug repurposing (Phillips 2008; Han et al. 2017; Quan et al. 2018; Yip et al. 2018) . Coincidentally, network control methods mainly focus on how to identify key nodes to control the whole network state from the initial state to the desired state. In this study, we aimed to develop techniques that bridge the connections between network control theory and the identification of personalized key disease genes (or KCGs) related to the transition between normal state and disease state. In fact, researchers have studied how to control biological network dynamics for more than a decade, which therefore can provide an effective model for drug-induced network changes and prediction of personalized drug combinations (Li et al. 2018) . Recently, we began to focus on how to study the control problem of personalized patient systems, and introduced a tool called Single Sample Controller (Guo et al. 2018a) , which applies network control to a single patient ecosystem to find driver genes related to the transition between normal and tumor state. Despite intense efforts to develop a scalable and accurate key control gene identification algorithm (Guo et al. 2018a) , this SCS algorithm can only use the linear control techniques, which contradict the dynamics of biological networks, particularly for a patient-specific system. Currently, we still lack a rigorous mathematical controllability model for nonlinear dynamic personalized patient system due to the unavailability of personalized data with small sample numbers but large dimension genes. Here, we considered the issue of identification of personalized drug combinations (a typical control problem on nonlinear biological networks in cancer genomics), and proposed a novel and efficient framework, called PDC (software freely avalable at http://sysbio.sibcb.ac.cn/cb/chenlab/software.htm) to fill the gap between network control theory and biological network control problem. The key consideration of PDC is to construct proper transition network between any two attractors of biological networks. In that, we can push a complex, nonlinear individual system in cancer from attractor (tumor) to attractor (normal) through by perturbing a feasible subset of network nodes (e.g., drug-target genes). In this study, we present a personalized drug controller method (PDC), which revealed the transition mechanism from a cancerous state to a normal state, as well as the cancer ecosystem of each patient at an individual level. Technically, PDC considers how to construct the personalized network capturing the phenotypic transitions between normal and disease states. This is accomplished by utilizing a paired SSN method to obtain the personalized transition network and applying our nonlinear structural control algorithm, called NCUA, based on feedback vertex sets to find the optimal patient-specific KCGs based on phenotype transitions, which can control the individuals from normal state to disease state, or vice versa. We applied PDC to BRCA and LUSC datasets from TCGA, whose validation results suggested that PDC with NCUA can identify known drug combinations for a single patient more efficiently than other existing network control methods. Our PDC approach also enabled patient stratification and prognostication with significant risk assessment.
Therefore, this study has provided novel insights into tumor heterogeneity in complex patient ecosystems.
Methods
The framework of PDC
Constructing personalized transition networks by using a paired-SSN method
First, the co-expression network of the tumor sample network or normal sample network for each patient was constructed based on statistical perturbation analysis of one sample against a group of given reference samples (e.g., choosing the normal sample data of all of the patients as the reference data) with SSN method (Liu et al. 2016) . If the differential PCC ( PCC  ) of an edge was statistically significantly large based on the evaluation of our SSN method, this edge would be kept for the single sample (normal sample or tumor sample) from each patient (Figure 1 and Figure   S1 ). The PCC  of an edge between gene i and j and its significant z-score were calculated by using the following formulae:
where n ij PCC is the Pearson correlation coefficient (PCC) of an edge between gene i and j in the reference network with n samples; 1 n ij PCC  is the Pearson correlation coefficient of the edge between gene i and j in the perturbed network with one additional sample, given a new sample (normal sample or tumor sample) for each patient being added to the reference group. In addition, the P-value for an edge could also be obtained from the statistical Z-value. All of the edges with significant differential correlations (e.g., p-value<0.05) were used to constitute the SSN for the normal sample or tumor sample.
We then constructed the personalized differential co-expression network between normal sample network and tumor sample network where the edge between gene i and gene j existed if the p-value of the edge was less than (greater than) 0.05 in the tumor network but greater than (less than) 0.05 in the normal network for their corresponding patient. Additionally, we defined the differential log2 fold-change between the tumor network edge and the normal network edge as the weight of the reserve edge by using the following formula: 2 log ( )
Finally, we obtained personalized transition state gene networks where edges existed in both gene interaction network and the differential co-expression network for each patient (Figure 1 and Figure S1 (a) ). By integrating gene interaction networks and personalized differential co-expression networks, personalized transition state gene networks couljd reveal which gene pairs were involved in the disease development for each patient. A personalized transition state gene network is an undirected graph where nodes represent genes, and a pair of nodes is connected by an edge if there is a significant expression correlation difference for the gene pairs between the tumor network and normal network. In addition, the edge weight was quantified by the differential fold change of gene pairs between normal sample and tumor sample for a patient, and the node weight is a confidence score for each gene denoting the regulatory impact on the state transition as calculated with the following formula:
where N(i) represents the neighborhood nodes set of node i in the gene state transition network.
Identifying personalized KCGs based on phenotypic transitions by NCUA method
Structural controllability analysis of network (Lin 1974) has become an important branch of network control. Particularly for biological complex networks, structural control has been widely applied and discovered many interesting properties of biological systems. However, the existing control methods Gao et al. 2014; Wu et al. 2014b; Guo et al. 2017; Guo et al. 2018d ) cannot be directly applied to the above constructed personalized transition state gene networks with a nonlinear and undirected dynamic because they are focused on linear dynamic directed networks. Therefore, an effective nonlinear network control strategy is required to characterize personalized transition state gene networks, and support selecting specific KCGs based on phenotypic changes.
Theoretically, the following typical dynamic ODE can be used to represent the dynamic behavior of a patient-specific system:
where i k x denotes the expression state of gene k for the patient I, I k represents the neighborhood gene set of gene k, () f represents the dynamic behavior control law of the patient-specific network for patient i, taking into account continuous differentiability, dissipativity, and decay condition (Fiedler et al. 2013a; Mochizuki et al. 2013 ). This dynamic equation represents the dynamic behavior of the gene expression level in the patient-specific network for patient i. In this work, we were interested in how to change the gene expression level from the disease state to normal state by using the optimal KCG set under this nonlinear dynamic behavior condition.
In this paper, a novel nonlinear control algorithm of undirected networks (NCUA) was designed based on structural control theory with Feedback vertex set (FVS) to ensure that the state of a system can be determined by the state of genes under nonlinear dynamic laws. The definition of FVS is a subset of nodes in the graph, such that the removal of the set leaves the graph without cycles. Therefore, the impetus behind our NCUA was to define an index to represent the quality of the KCG and apply a linear integer program to identify the optimal FVS with maximum quality as the KCG set. Figure S1 (b) illustrates the process of our NCUA for discovering the optimal KCG set. The details of NCUA are provided below.
1) Constructing dominant gene sets based on the FVS structure control theory
In a directed network, if I is used to represent the Feedback Vertex Set (FVS), then the state of the entire network can be determined by the state of the feedback node set I, called FVS structural control theory (Fiedler et al. 2013a; Mochizuki et al. 2013 
2) Selecting optimal KCGs from candidate dominant gene sets by using linear integer programming
It is known that different dominant gene sets will have different controlling costs on patient-specific networks. Therefore, we introduced an index (e.g., cost function) to indicate the quality of the selected KCG:
where i w denotes the confidence score of gene i by summarizing the scores of its connected edges in a patient-specific network by using formula (4) For the control problem modeled by PDC, we expected that the selected set of KCGs would not only contain the minimum gene number, but would also have the maximum differential fold change scores of genes. Therefore, it could be used to further measure the quality of the candidate KCG set, and we selected the optimal KCGs by solving the following linear integer programming:
where L V denotes the node set of the low side in the (converted) bipartite graph and u N denotes the neighborhood node set in the bipartite graph; the objective function is to obtain the KCG set with the minimum number but the maximum differential fold change scores. The restriction condition is to ensure that all the edges of the original network in the bipartite network can be covered. Thus, under the nonlinear dynamic behavior, the state of all of the nodes (genes) in a patient-specific network can be regulated by the KCG. The above optimization problems can be effectively solved by the classical LP-based classic branch and bound method (Lenstra 1983; Williams 1990 ).
Note that the nonlinear control problem of undirected networks (NCUA) is firstly proposed in our recent new paper (Guo et al. 2018b ). This new version NCUA used here focus on the optinal key control nodes set (KCGs) while the first version focus on the minimum number of key control nodes set and the multiple control configurations in controlling the undirected nonlinear networks. From this perspective, this version NCUA is more suitable for network control problems in both theory and application.
3) Prioritizing personalized anti-cancer drug combinations
In this work, the impact score of a given drug combination was calculated based on the number of targeting personalized KCGs for each cancer patient using nonlinear structural control method based on feedback vertex sets. We ranked and prioritized potential personalized drug combinations based on their impact on personalized KCGs.
Statistical test of the functional and structural properties of personalized KCGs
(1) Mutational level test. This test examined whether personalized KCGs were significantly enriched in patient-specific mutational profiles. We used the following test to evaluate the mutational level (SNP mutation data) of KCGs. The random data sets with the same number of disease genes were first obtained and we then computed z-score as:
where n i is the mutational level (the intersected gene number of disease genes and genetic mutations) of KCGs for patient i. SD i is the distribution of the mutational level of generated random genes with the same number of disease genes. Mean and standard deviation of SD i were computed from 100 simulations of random data sets. Based on the z-score, we obtained the empirical P-value, i.e., P i (modeled as Gaussian distribution). The significant P-values for the mutational level were obtained for each patient, where the alternative hypothesis (H1) is n i > n 0 , and n 0 is mean value of the mutational level of generated random genes with the same number of disease genes.
(2) Differential expression level test. This test determined if the differential expression level of personalized KCGs were significantly higher than the random gene sets. We used the test outlined above to evaluate the differential expression level of the personalized genes. In the calculation of z-score, n i is the differential expression level (the absolute value of log2 fold change between normal expression data and tumor expression data) of KCGs for patient i. SD i is the distribution of the differential expression gene level of generated random genes with the same number of KCGs. Mean and standard deviation of SD i was computed from 100 simulations of random data sets. For the differential expression level test, the alternative hypothesis (H1) is n i < n 0 , where n 0 is mean value of the differential expression gene level of generated random genes with the same number of disease genes. (4) Epistasis-interaction test. Recently many studies have proposed that targeting interacting disease-related genes (epistatic genes) may bring synergistic effects for disease control, and drug combinations aimed at epistatic genes may have higher medicinal potential (Phillips 2008; Han et al. 2017; Quan et al. 2018; Yip et al. 2018 ). For the epistasis-interaction test, we calculated the number of edges among the disease genes. We then generated 100 random networks, each of which maintained the topological characteristics of the original network (degree of each node) and recalculated the number of edges among the disease genes. We then used a one-tailed Fisher exact test to obtain the p-value for evaluating whether the KCGs were significantly more connected than the random genes.
Quantification of side effect scores on targets
In this section, we introduce the method for calculating the side effect score of a given drug pair on the drug-target network (Torres and Altafini 2016) . The classification of drug actions into positive and negative modes of action allowed us to characterize the effect of multiple drugs acting on the targets. Two drugs sharing the same target tended to reinforce their effect on the target if their modes of action were similar, while they tended to mitigate the overall effect if they had opposing modes of action.
The three possible combinations of a drug pair effect on a common target (+,+), (−,−), and (+,−) are shown in Figure S4 . The two combinations (+,+) and (−,−) will be referred to as coherent, as the action of one drug was reinforced by the presence of a second drug. In the remaining combination (+,−), the presence of a second drug counteracted (and hence in general reduced) the action of the first drug. This configuration will be called incoherent. If all drug-target interactions can be classified as pharmacological (on-target actions) and non-pharmacological (off-target actions)
by attaching signs to the mechanisms of action (Torres and Altafini 2016) , the side effect score can be calculated by using the following formula: 
where s ij is the number of common targets of the drug pair (i, j), which are not pharmacological targets in DrugBank for at least one of the two drugs; 
Availability of data and materials
All of the data resources used in this study, including the cancer benchmark datasets and the reference network datasets , are provided for free at http://sysbio.sibcb.ac.cn/cb/chenlab/software.htm. The source code of PDC with NCUA and other network control methods, are also provided for free at http://sysbio.sibcb.ac.cn/cb/chenlab/software.htm.
